New Directions in the Treatment of Relapsed/Refractory DLBCL: Implications for Practice
 |
New Directions in the Treatment of Relapsed/Refractory DLBCL: Implications for Practice CME, CPE James O. Armitage, MD; and Matthew Lunning, DO, FACP |
|
| Release Date: October 28, 2022 Expiration Date: October 28, 2023 |
||
|
In this activity, Dr. Lunning will address key data from recent publications and conferences on current and emerging approaches for the treatment of relapsed/refractory DLBCL. To conclude, Dr. Armitage and Dr. Lunning will discuss current and potential practice implications. Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol Myers Squibb and Genentech, a member of the Roche Group. |
||
| Begin, Earn CreditView Only, No Credit | ||